Dan-Arin Silasi MD

Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Women's Reproductive Cancers Program | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., University of Medicine and Pharmacy of Timisoara, Romania (1993)
  • Resident, University of Texas Health Science Center , Obstetrics/Gynecology (2001 - 2005)
  • Resident, New York University Harbor Healthcare System , Internal Medicine (1999 - 2001)
  • Fellow, Yale University School of Medicine , Gynecologic Oncology

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Gynecologic cancers (ovarian, uterine, cervical, vulvar, and vaginal cancers); Gestational trophoblastic neoplasia; Complicated laparoscopic surgery; Robotic surgery; Single-port laparoscopic surgery; Advanced and complicated pelvic surgery; Chemotherapy for gynecologic cancers


Cancers Treated

Cervix, Gestational Trophoblastic Neoplasia, Ovary, Uterus, Vagina & Vulva


Board Certifications

  • Obstetrics & Gynecology, Board Certified (2010)
  • Gynecologic Oncology, Board Certified (2012)

Clinical Trials

ConditionsStudy Title
Endometrial Cancer and Corpus UteriA Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (GOG 0258) (CIRB)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Other Female Genital, and OvaryChemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG 0273)
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.

Edit Profile